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Available online 28 November 2017The role of serum uric acid (SUA) as a prognostic marker for incident heart failure (HF) in hypertensive subjects
is uncertain. We have prospectively examined the relationship between SUA and incident HF in 3440 men aged
60–79 years separately in those on and not on antihypertensive treatment who were followed up for a mean
period of 15 years. Men on SUA lowering drugs and those with history of HF or myocardial infarction were
excluded. Therewere 260 incident HF cases. Themenwere divided into three groups of SUA concentrations/levels
(b350, 350–410 and N410 μmol/L). Raised SUA was associated with signiﬁcantly increased risk of HF in men on
antihypertensive treatment (N= 949) but not in those without (N= 2491) (p= 0.003 for interaction). In men
on antihypertensive treatment those with hyperuricemia (N410 μmol/L) had the most adverse biological risk
proﬁle for HF including the highest rates of atrial ﬁbrillation and renal dysfunction and the highest mean
level of BMI, c-reactive protein and cardiac function (cardiac troponin T). Treated hypertensive men with
SUA levels N 410 μmol/L showed an increase in risk of HF of more than twofold compared to those on treat-
ment with levels b350 μmol/L even after adjustment for lifestyle characteristics and biological risk factors
[adjusted hazard ratio 2.26 (1.23,4.15)]. SUA improved prediction of HF beyond routine conventional risk
factors (p = 0.02 for improvement in c-statistics). SUA as a marker of increased xanthine oxidase activity
may be a useful prognostic marker for HF risk in older men on antihypertensive treatment.e and Po
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Serum uric acid (SUA) is the end product of purine metabolism in
humans; hyperuricaemia is commonly found in patients with heart fail-
ure (HF) and hypertension [1,2]. The association of SUA and coronary
heart disease has long been recognised [1] andhas sparked enormous de-
bate about the role of SUA as a risk factor for CHD and the treatment of
hyperuricemia especially in hypertensive patients [1,3–5]. Inmore recent
years several studies and meta-analysis have reported raised SUA to be
associated with increased risk of incident HF in population studies
[6–10].Whether this association is causal is still amatter of debate. How-
ever a recent Mendelian randomisation study provided no evidence that
the association between SUA and HF is causal, suggesting that SUA may
be only a risk marker rather than a causal factor in the development of
HF [11]. Hypertension is a major risk factor for HF and regardless of
whether SUA is causally related to HF, SUA may be a useful biomarker
of increased HF risk in hypertension [12]. Recent studies have shown apulation Health, UCL
2PF, UK.
).
and freedom from bias
This is an open access articlstrong association between SUA levels and AF [13], a major risk factor
for HF and one study has shown SUA to predict HF in those with hyper-
tension [14]. SUA is dependent on xanthine oxidase (XO) activity, a
known cause of oxidative stress [15] which is implicated in the patho-
physiology of HF [15,16] as well as hypertension [17]. SUA may be a
marker of increased XO activity which is up-regulated in the failing
heart [15] and may thus identify patients with increased HF risk. SUA
concentration is commonly measured in hypertensive patients and
although a number of studies have shown SUA to be an independent
marker of CVD risk in hypertensive subjects [18,19], there is limited pro-
spective data regarding the association between raised SUA andHF, espe-
cially in the older hypertensive adult population, who are at particularly
high risk of developing HF. Whether SUA add to the prediction of HF be-
yond routine markers in older hypertensive patients has seldom been
assessed. We have therefore examined the association between raised
SUA and incident HF in older men who are on antihypertensive treat-
ment, as well as in those who are not on antihypertensive treatment.
2. Subjects and methods
The British Regional Heart Study is a prospective study involving 7735 men aged
40–59 years drawn from one general practice in each of 24 British towns, who were
screened between 1978 and 1980 [20]. The population studied was socio-economically
representative and comprised predominantly white Europeans (N99%). In 1998–2000,e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tion, on which the current analyses are based. Ethical approval was obtained from all
relevant local research ethics committees. All men completed a mailed questionnaire
providing information on their lifestyle and medical history, had a physical examination
and provided a fasting blood sample. The samples were frozen and stored at−20 °C on
the day of the collection and transferred in batches for storage at−70 °C until analysis,
carried out after no more than one freeze-thaw cycle. 12 lead electrocardiograms were
recorded using a Siemens Sicard 460 instrument and were analyzed using Minnesota
Coding deﬁnitions at the University of Glasgow ECG core laboratory. Men were asked
whether a doctor had ever told them that they had angina or MI, HF or stroke; details of
their medications were recorded at the examination including use of blood pressure
lowering drugs (BNF code 3.1) and non-steroidal anti-inﬂammatory drugs (NSAIDs)
(BNF code 10.1.1). 4252 men (77% of available survivors) attended for examination.
4034men had bloodmeasurement of SUA.We excludedmenwith prior HF ormyocardial
infarction (MI) (N=508) in the examination and a further 86men on treatment for gout
(SUA lowering drugs) leaving 3440 men for analysis.
2.1. Cardiovascular risk factor measurements at 1998–2000
Anthropometric measurements including body weight and height were carried out.
Details of measurement and classiﬁcation methods for smoking status, physical activity,
social class, alcohol intake, blood pressure and blood lipids in this cohort have been
described [21,22]. SUAwasmeasuredwith an enzymatic colorimetric assay using aHitachi
747 automated analyser. C-reactive protein (CRP) (marker of inﬂammation) was assayed
by ultra sensitive nephelometry (Dade Behring, Milton Keynes, UK). Predicted glomerular
ﬁltration rate (eGFR) (measure of renal function) was estimated from serum creatinine
using the equation eGFR = 186 × (Creatinine / 88.4)−1.154 × (Age)−0.203 [23].
N-terminal pro-brain natriuretic peptide (NT-proBNP) was determined using the Elecsys
2010 (Roche Diagnostics, Burgess Hill, UK) [22]. Troponin T was measured by a high sen-
sitivity method on an e411 (Roche Diagnostics, Burgess Hill, UK) using themanufacturers
calibrators and quality control material. The low control CVwas 6.6%, and high control CV
3.0%, and the assay limit of detection was 3 pg/ml. Electrocardiographic left ventricular
hypertrophy (LVH) was deﬁned according to the relevant Minnesota codes (codes 3.1 or
3.3). Atrial ﬁbrillation (AF) was deﬁned according to the Minnesota codes 8.3.1 and 8.3.3.
2.2. Follow-up
All men have been followed up from initial examination (1978–1980) for cardiovas-
cular morbidity [20] and follow-up has been achieved for 99% of the cohort. In the present
analyses, all-cause mortality and morbidity events are based on follow-up from re-
screening in 1998–2000 at mean age 60–79 years to June 2014, a mean follow-up period
of 15 years (range 14–16 years). Survival times were censored at date of HF, death from
any cause or end of the study follow-up period (June 2014) whichever occurred ﬁrst.
Evidence of non-fatalMI andHFwas obtained by adhoc reports from general practitioners
supplemented by biennial reviews of the patients' practice records (including hospital and
clinic correspondence) to the end of the study period. Incident non-fatalHFwas based on a
conﬁrmed doctor diagnosis of HF from primary care records and conﬁrmed by a review
of available clinical information from primary and secondary care records (including
symptoms, signs, investigations, treatment response) to ensure that the diagnosis was
consistent with the current recommendations on HF diagnosis [24]. The incidence and
determinants of HF cases identiﬁed using this process have already been reported and
are consistent with the results from other studies [21,22]. Incident HF included incident
non-fatal HF aswell as death fromHF (ICD 9th revision code 428 or ICD10th revision I28).
2.3. Statistical methods
Themenwere divided into three groups based on the tertile distribution of SUA in all
men (b350, 350–410 and N410 μmol/L). Hyperuricemia in men is generally deﬁned as
those with SUA N420 μmol/L [25]. Thus those in the upper tertile were effectively
hyperuricaemic. Kaplan–Meier methods were used to calculate the cumulative HF
incidence for the three groups of SUA; the log-rank test was used to evaluate differences
in the HF rates for these groups. Analyses were carried out stratiﬁed by antihypertensive
treatment status. Cox proportional hazards model was used to assess the multivariate-
adjusted hazards ratio (HR) in a comparison of the three SUA groups as well as in a 1 SD
increase in SUA. The proportional hazard assumption was examined using time-varying
covariates, calculating interactions of predictor variables and a function of survival time
and including them in the models. Examination of time-varying covariates indicated no
violation of the proportionality assumption. The distributions of NT-proBNP, cTnT and
CRP were skewed and log transformation was used to normalise these factors. Receiver-
operating characteristic (ROC) curves and areas under the curve (AUC) (c-statistics)
were used to assess the ability of SUA to predict HF inmen on antihypertensive treatment
and who had no history of HF or MI beyond a score which included conventional routine
risk factors as well as how SUA predicted beyond the Health ABC HF score. Conventional
routine risk factors included established risk factors for HF routinely obtained in clinical
practice e.g. age obesity, hypertension, history of diabetes and history of angina. The
Health ABC HF score includes age, smoking, eGFR, heart rate, left ventricular hypertrophy,
albumin, systolic blood pressure, history of angina, fasting blood glucose and antihyper-
tensive treatment [26]. To assess whether the association between SUA and incident HF
may be due to the development of incident CHD which in turn results in increased risk
of HF, we adjusted for incident CHD by ﬁtting CHD as a time dependent covariate.3. Results
During the mean follow-up period of 15 years there were 260
incident HF events (6.31/1000 person years), in the 3440 men without
MI or HF and who were not on SUA lowering drugs.
Fig. 1 show the Kaplan–Meier estimates of the cumulative incidence
of HF by tertiles of SUA separately by antihypertensive treatment status.
Risk of HF was increased only in those in the top tertile of the SUA dis-
tribution, and this was only seen inmen on antihypertensive treatment.
No associationwas seen between SUA and HF in those not on treatment
and a test for interaction conﬁrmed a signiﬁcant difference in the rela-
tion between SUA and incident HF in those on and not on antihyperten-
sive treatment (p= 0.02). We therefore present the ﬁndings stratiﬁed
by antihypertensive medication status.
Table 1 shows the association between SUA and biological risk
factors in men on and not on antihypertensive treatment. With the ex-
ception of blood pressure, the patterns of association between SUA and
biological risk factorswere similar in bothmen on and not on treatment.
Men on antihypertensive treatment with raised SUA had the highest
levels of cardiovascular risk factors including renal dysfunction, AF,
systolic blood pressure, cTnT and the lowest level of HDL-C and FEV1.
In men not on antihypertensive treatment, no association was seen
between SUA and HF (Table 2). When this group was separated into
those with measured hypertension (systolic blood pressure ≥ 160 or
DBP ≥90) and those without, no association was seen in either group
(data not shown). In contrast, in men on antihypertensive treatment,
hyperuricemia (N410 mmol/L) was signiﬁcantly associated with
increased risk of HF even after adjustment for a wide range of HF
risk factors including AF, BMI, HDL-C, systolic blood pressure, renal dys-
function, CRP and cardiac function (NT-proBNP and cTnT). Further
adjustment for incident CHD made little difference to the ﬁndings.
The increased risk of HF associated with hyperuricaemia remained
even after exclusion of men on diuretics [adjusted HR = 1.97
(1.01,3.81);model 4] or exclusion of men with renal dysfunction
[adjusted HR = 2.56 (1.30,5.02);model 4] or the exclusion of 84 men
on NSAIDs [adjusted HR = 2.37 (1.29,4.35); model 4].
The elevated risk associated with hyperuricaemia was seen in those
with controlled blood pressure (deﬁned as systolic blood pressure b 150
and diastolic blood pressure b 90;N=321) and thosewith uncontrolled
blood pressure (N = 585) although the association was somewhat
stronger in those with controlled hypertension compared to those
with uncontrolled blood pressure (adjusted HR = 4.70 (1.53,14.44) vs
2.09 (0.98,4.48);model 4]. However a test for interaction was not
signiﬁcant (p= 0.47).
Table 3 shows the c-statistics for the conventional risk score and
the Health ABC HF score and the improvement in C-statistics in models
with and without SUA. SUA added signiﬁcantly to HF prediction
beyond that provided by either risk score. However, a model which
included conventional risk factors and NT-proBNP showed no sig-
niﬁcant improvement on the addition of SUA [c statistic = 0.676
(0.624–0.728) versus 0.691 (0.640–0.742) with SUA]; evidence for
improvement p= 0.14].
4. Discussion
In this study of older men with no history of an MI or HF raised SUA
was associated with signiﬁcantly increased risk of HF which was only
seen in those who were on antihypertensive treatment. No association
was seen between SUA andHF risk in thosewhowere not on antihyper-
tensive treatment. Our ﬁnding extends those of previous studies of SUA
and HF by examining the relationship by antihypertensive medication
status and by examining the prognostic value of SUA and improvement
in risk prediction in thosewith hypertension. The increased risk of HF in
those on treatment was seen even after adjustment for a wide range
of HF risk factors including renal dysfunction, inﬂammation and cardiac
function (NT-proBNP and cTnT). In a recent meta-analysis which
Fig. 1. Kaplan-Meier curve of cumulative heart failure incidence by tertiles of SUA in men on antihypertensive treatment and in men not on antihypertensive treatment. Log rank test:
Men not on antihypertensive treatment p= 0.57; Men on antihypertensive treatment p b 0.001;
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CVD morbidity and mortality in hypertensive patients [19] and our
ﬁndings extend this to HF outcome.
4.1. SUA and incident HF
A number of prospective studies andmeta-analysis have shown SUA
to predict HF in the general population [6–10]. However, few studies
have examined the relationship by antihypertensive treatment status.
We have shown SUA to be associated with increased risk of HF in thegeneral population but this was only seen in those on treatment.
Although numerous studies have examined the association between
SUA and risk of CHD events and CVDmortality in hypertensive patients
few studies have reported on the speciﬁc effect of SUA on HF risk in
hypertensive patients. The Primary Preventive Trial in Goteborg showed
that SUA predicted HF in treated hypertensives [14]. However, in the
Cardiovascular Health Study SUA did not predict HF in those with
hypertension or those on antihypertensive treatment [10]. The reason
for this discrepancy is uncertain but it may relate to the use of SUA
lowering drugs in hypertensive subjects as these patients were not
Table 1
SUA and biological risk factors in men on and not on antihypertensive treatment.
Men not on treatment N410 p-Difference Men on treatment N410 p-Difference
SUA (μmol/L) SUA(μmol/L)
b410 b410
No of men 1871 668 485 418
Type of BP treatment
% BB 41.4 39.2 0.50
% diuretics 20.2 31.6 b0.0001
% ACEi 16.5 34.2 b0.0001
Age 68.2 (5.5) 68.1 (5.4) 0.86 69.4 (5.5) 69.7 (5.2)
%AF 1.7 3.0 0.03 4.7 7.7 0.07
% renal dysfunction 8.2 20.1 15.7 28.7
% LVH 6.5 7.5 0.37 10.1 10.8 0.75
BMI kg/m2) 26.1 (3.4) 27.5 (3.5) b0.0001 27.0 (3.5) 28.4 (3.8) b0.0001
SBP (mmHg) 147.0 (23.7) 150.4 (22.4) b0.0001 155.8 (25.0) 156.6 (23.4) 0.62
HDL-C 1.38 (0.35) 1.29 (0.34) b0.0001 1.32 (0.35) 1.23 (0.30) b0.0001
Log HOMA-IR 0.66 (0.71) 0.84 (0.66) b0.0001 0.88 (0.84) 1.04 (0.70) 0.001
FEV1 (L) 2.68 (0.68) 2.62 (0.63) 2.50 (0.61) 2.48 (0.62) 0.63
CRP (mg/L)⁎ 1.46 (0.67–2.95) 1.77 (0.90–3.60) b0.0001 1.99 (0.95–3.93) 2.29 (1.16–4.66) 0.06
Heart rate (b/min) 65.60 (11.4) 67.73 (13.2) b0.0001 64.9 (14.2) 64.7 (14.95) 0.81
NT-proBNP (pg/ml)⁎ 76.7 (40–141) 76.7 (36–147) 0.93 127.7 (64–269) 144.0 (61–275) 0.74
cTnT (pg/ml)⁎ 11.0 (8.2–14.8) 12.1 (8.9–15.9) b0.0001 11.8 (9.0–15.7) 13.5 (9.7–17.7) 0.0002
⁎ Geometric mean (IQ range).
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affect the true association of hyperuricemia with HF if those on SUA
lowering drugs were included in the normal SUA group. We have
shown that SUA improves prediction in HF risk beyond routine clinical
risk factors for HF including BMI, hypertension, renal dysfunction pre-
existing diabetes, stroke and angina. SUA also improved prediction be-
yond that provided by the ABC heart failure score. Although SUA did
not improve HF risk prediction beyond NT-proBNP, SUA is a routine
marker and easily measured in primary care and may help identify
high risk subjects whowould beneﬁt from further evaluation of cardiac
dysfunction and AF.
The ﬁndings that SUA predicts HF in those on treatment only
suggests that SUA does not have an intrinsic relationship with HF but
may be a marker of other pathways.
Raised SUA could also be due to impaired renal clearance and in-
creased production of urate and renal dysfunction has been associated
with HF risk. We have shown a strong association between renal dys-
function and SUA but the increased risk of SUA and HF was seen even
after exclusion of men on diuretics or men with renal dysfunction.Table 2
Rates/1000 person-years and adjusted hazard ratios (HR) (95%CI) for incident HF by serum ur
Serum uric acid (μmol/L)
b350 350–410
All men
No of men 1186 1170
per-yrs (n) 4.8 (67) 5.8 (82)
Not on antihypertensive treat
No of men 948 923
Rate/1000 per-yrs (n) 4.5 (50) 5.4 (61)
Age-adjusted HR 1.00 1.16 (0.80,1.69)
Model 1 1.00 1.24 (0.84,1.83)
On antihypertensive treatmen
No of men 238 247
Rate/1000 per-yrs. (n) 5.6 (15) 7.2 (20)
Age-adjusted HR 1.00 1.30 (0.66,2.56)
Model 1 1.00 1.44 (0.72,2.90)
Model 2 1.00 1.44 (0.71,2.90)
Model 3 1.00 1.54 (0.76,3.13)
Model 4 1.00 1.43 (0.71,2.89)
Model 1 adjusted for age, smoking, social class, alcohol intake, physical activity, BMI, HDL-C, di
Model 2 = Model 1 + AF + renal dysfunction + CRP.
Model 3 = Model 2 + NT-proBNP.
Model 4 = model 2 + cTnT.SUA has been associated with increased risk of developing AF [13] and
SUA was associated with prevalent AF but adjustment for AF did not
alter the ﬁndings. We did not have information on AF during follow-
up and it is possible that part of the association may be mediated by
the development of AF. Elevated serum SUA could be amarker of under-
lying tissue ischaemia [27]. The ﬁnding that SUA was associated with
cTNT suggests that it may be detecting men with sub-clinical cardiac
dysfunction. However although part of the association was mediated
by cTnT, the association remained after further adjustment for cTnT.
We observed no association between SUA and NT-proBNP a marker of
ventricular stress. Thus the increase risk of HF in hyperuricemic men
compared to normouricemia men is unlikely to be due to the presence
of asymptomatic HF.
4.2. SUA and xanthine oxidase activity
Evidence from a number of studies suggests that hyperuricaemia is
associatedwithHFwhen it is amarker of increased xanthine oxidase ac-
tivity [9,10]. The ﬁnding that SUA predicted HF in hypertensive treatedic acid levels in men with no prevalent MI or HF by antihypertensive status.
N410 Increase in 10 μmol/L p-Trend
1084
8.6 (111)
ment
668
5.4 (43)
1.23 (0.83,1.83) 1.013 (0.991,1.035) 0.25
1.11 (0.73,1.70) 1.005 (0.983,1.028) 0.65
t
418
13.6 (63)
2.39 (1.36,4.21) 1.033 (1.011,1.056) 0.003
2.59 (1.42,4.75) 1.035 (1.010,1.061) 0.006
2.49 (1.36,4.56) 1.035 (1.011,1.061) 0.004
2.42 (1.29,4.54) 1.028 (1.002,1.054) 0.02
2.26 (1.23,4.15) 1.027 (1.001,1.050) 0.04
abetes, SBP, prevalent stroke, prevalent angina.
Table 3
Improvement in c statistics for conventionalmodels and the ABC health scoremodelswith
and without NT-proBNP and SUA in men on antihypertensive treatment and with no
diagnosed MI or HF.
Model c-statistics p-Value improvement
Conventional risk factors 0.621 (0.567,0.675) –
Conventional risk factors + SUA 0.654 (0.601,0.707) p= 0.02
ABC score 0.617 (0.565,0.671) –
ABC score + SUA 0.649 (0.597,0.701) p= 0.02
Conventional risk
factors + NT-proBNP
0.676 (0.624,0.728) –
Conventional risk
factors + NT-proBNP + SUA
0.691 (0.640,0.742) p= 0.14
Conventional risk factors (routine clinical risk factors) include age, BMI, systolic blood
pressure, renal function, history of diabetes, stroke and angina.
ABC score include age, smoking, eGFR, heart rate, left ventricular hypertrophy, albumin,
systolic blood pressure, history of angina and fasting blood glucose.
SUA ﬁtted as tertiles in the model.
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the metabolism of purines by XO. XO activity has been shown to play
an important role in the pathogenesis of hypertension [17] and is
also involved in the production of reactive oxygen species (ROS).
Experimental and animal models suggest that oxidative stress which
is characterised by excessive production of reactive oxygen species
(ROS) and reduction of antioxidant defence capacity may play an im-
portant role in the pathophysiology of HF [28]. Hyperuricemia in the
presence of essential hypertension may be a compensatory response
to counteract excessive oxidative stress and thus represent a marker
of increased XO expression activity and oxidative stress.
4.3. Lowering of SUA and CVD
There has been much debate on the potential beneﬁts of lowering
SUA levels and in recent yearsmuch attention has focused on the poten-
tial beneﬁts of XO inhibitors [4]. A recent Cochrane review concluded
that there is insufﬁcient evidence for use of allopurinol an XO inhibitor,
or other uric acid lowering drug as the initial treatment of hypertension
[5]. However, most trials have focused on CVD or CHD as the end point
and few have examined HF speciﬁcally. A recent observational study in
gout patients showed no reduction in risk of HF in those on XO inhibi-
tors compared to untreated hyperuricaemia [29]. However, the beneﬁts
of XO may only be apparent in selected high risk patients and in those
with increased oxidative stress such as in older hypertensive subjects
in whom hyperuricemia may be a marker of XO activity. Trials in
subjects such as diabetes and hypertensive patients have shown beneﬁ-
cial effects of allopurinol on endothelial dysfunction, left ventricular
hypertrophy and arrhythmias [30], major risk factors for HF. However,
whether the use of XO inhibitors in hypertensive patients reduces
incident HF is yet to be established.
4.4. Strengths and limitations
The strength of this study is as a representative cohort with a wide
range of HF risk factors measured and high follow up rates. However,
it was based on an older, predominantly white, male population of
European origin, so that the results cannot be generalized directly to
women, or to younger populations or other ethnic groups. The current
ﬁndings are based on doctor diagnosed HF, which is likely to underesti-
mate the true incidence of HF in this study population. However, the
other risk factor associations toHF risk in this report and in our previous
report on obesity, NT-proBNP and lung function and HF [21,22,31] gen-
erally accord with prior data and therefore suggest potential external
validity for our ﬁndings. Information on echocardiogrammeasurements
was not available andwewere not therefore able to differentiate systol-
ic and diastolic HF. SUA was only measured at a single point in time,
so that strengths of associations may be underestimated.4.5. Clinical implications and conclusion
In this study we have shown SUA to be associated with increased
risk of HF in older men on antihypertensive treatment which is inde-
pendent of known risk factors. The ﬁndings that hypertensive men
with hyperuricaemia had themost adverse risk proﬁle for HF (including
underlying ischaemia, atrial ﬁbrillation, inﬂammation), raises the issue
ofwhether SUA levels should be routinelymonitored in older hyperten-
sive patients in primary care. Directmeasurement of XO is difﬁcult; SUA
is easy to measure and may be a marker of XO activity in hypertension.
Current guide lines in the National Institute for Health and Care
Excellence (NICE) do not include SUA in the list of risk factors review
for cardiovascular disease. Measurement of SUA in older hypertensive
patients in primary care may help identify high risk patients who may
beneﬁt from further evaluation of subclinical cardiac dysfunction and
pharmacological intervention. Primary intervention trials in older hy-
pertensive people at high risk of HF are needed to conﬁrm whether
XO inhibitors would reduce risk of HF in this group.
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